Is muscarinic receptor agonist effective and tolerant for schizophrenia?

Abstract Background Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting muscarinic receptors improve symptom management and reduce side effects remains systemically un...

Full description

Bibliographic Details
Published in:BMC Psychiatry
Main Authors: Xiaonan Guo, Rongshan Deng, Jianbo Lai, Shaohua Hu
Format: Article
Language:English
Published: BMC 2025-04-01
Subjects:
Schizophrenia
Muscarinic receptor agonist
Xanomeline-trospium
Online Access:https://doi.org/10.1186/s12888-025-06662-1

Internet

https://doi.org/10.1186/s12888-025-06662-1

Similar Items